| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Silymarin | 102 | 2017 | 194 | 21.380 |
Why?
|
| Prostatic Neoplasms | 88 | 2022 | 913 | 13.420 |
Why?
|
| Chemical Warfare Agents | 24 | 2024 | 119 | 10.490 |
Why?
|
| Mustard Gas | 22 | 2024 | 117 | 8.880 |
Why?
|
| Apoptosis | 120 | 2023 | 2349 | 7.490 |
Why?
|
| Antineoplastic Agents, Phytogenic | 39 | 2019 | 181 | 7.250 |
Why?
|
| Mechlorethamine | 17 | 2024 | 63 | 6.970 |
Why?
|
| Skin | 31 | 2024 | 653 | 6.400 |
Why?
|
| Corneal Injuries | 8 | 2024 | 33 | 6.380 |
Why?
|
| Anticarcinogenic Agents | 23 | 2016 | 66 | 5.030 |
Why?
|
| Antioxidants | 37 | 2023 | 529 | 4.860 |
Why?
|
| Plant Extracts | 25 | 2020 | 154 | 4.750 |
Why?
|
| Cornea | 11 | 2024 | 102 | 4.500 |
Why?
|
| Cell Cycle | 37 | 2018 | 541 | 4.230 |
Why?
|
| Antineoplastic Agents | 38 | 2021 | 1875 | 4.150 |
Why?
|
| Cell Proliferation | 72 | 2021 | 2173 | 3.980 |
Why?
|
| Ultraviolet Rays | 22 | 2022 | 363 | 3.980 |
Why?
|
| DNA Damage | 23 | 2019 | 351 | 3.920 |
Why?
|
| Irritants | 13 | 2024 | 41 | 3.820 |
Why?
|
| Skin Neoplasms | 19 | 2022 | 754 | 3.730 |
Why?
|
| Neovascularization, Pathologic | 24 | 2018 | 280 | 3.380 |
Why?
|
| Cell Line, Tumor | 84 | 2023 | 2700 | 3.290 |
Why?
|
| Adenocarcinoma | 17 | 2022 | 787 | 3.270 |
Why?
|
| Animals | 160 | 2024 | 31565 | 3.120 |
Why?
|
| Phytic Acid | 11 | 2012 | 41 | 3.010 |
Why?
|
| Arsenicals | 5 | 2023 | 23 | 2.970 |
Why?
|
| Tumor Suppressor Protein p53 | 25 | 2019 | 445 | 2.860 |
Why?
|
| Carcinoma, Basal Cell | 5 | 2022 | 66 | 2.760 |
Why?
|
| Signal Transduction | 47 | 2020 | 4501 | 2.740 |
Why?
|
| Mice | 112 | 2024 | 14843 | 2.690 |
Why?
|
| NF-kappa B | 24 | 2016 | 636 | 2.640 |
Why?
|
| Cell Cycle Proteins | 21 | 2018 | 549 | 2.530 |
Why?
|
| Nitric Oxide Synthase Type II | 16 | 2016 | 157 | 2.480 |
Why?
|
| Mice, Hairless | 27 | 2020 | 74 | 2.330 |
Why?
|
| Momordica charantia | 4 | 2020 | 13 | 2.320 |
Why?
|
| Proto-Oncogene Proteins c-akt | 15 | 2018 | 397 | 2.170 |
Why?
|
| Rabbits | 14 | 2024 | 733 | 2.150 |
Why?
|
| Mice, Nude | 35 | 2020 | 628 | 2.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 14 | 2013 | 107 | 2.070 |
Why?
|
| Cyclooxygenase 2 | 20 | 2021 | 164 | 2.050 |
Why?
|
| Colorectal Neoplasms | 15 | 2014 | 592 | 2.010 |
Why?
|
| Cell Survival | 32 | 2021 | 1014 | 1.990 |
Why?
|
| Carcinoma | 9 | 2011 | 198 | 1.820 |
Why?
|
| Pancreatic Neoplasms | 6 | 2020 | 721 | 1.800 |
Why?
|
| Neoplasms | 16 | 2017 | 2086 | 1.790 |
Why?
|
| Xenograft Model Antitumor Assays | 26 | 2020 | 695 | 1.780 |
Why?
|
| MAP Kinase Signaling System | 10 | 2023 | 271 | 1.770 |
Why?
|
| Vitis | 15 | 2013 | 38 | 1.770 |
Why?
|
| Dexamethasone | 6 | 2024 | 316 | 1.720 |
Why?
|
| Oxidative Stress | 15 | 2023 | 1068 | 1.670 |
Why?
|
| Angiogenesis Inhibitors | 12 | 2019 | 213 | 1.630 |
Why?
|
| Dermatitis, Contact | 4 | 2013 | 23 | 1.610 |
Why?
|
| Vascular Endothelial Growth Factor A | 19 | 2019 | 496 | 1.600 |
Why?
|
| Mitogen-Activated Protein Kinases | 12 | 2020 | 269 | 1.600 |
Why?
|
| Protective Agents | 4 | 2017 | 37 | 1.600 |
Why?
|
| Phytotherapy | 10 | 2012 | 67 | 1.590 |
Why?
|
| Lung Neoplasms | 16 | 2016 | 2159 | 1.590 |
Why?
|
| Cadherins | 7 | 2018 | 175 | 1.580 |
Why?
|
| Male | 130 | 2022 | 55396 | 1.570 |
Why?
|
| Disease Models, Animal | 21 | 2024 | 3498 | 1.530 |
Why?
|
| Humans | 195 | 2024 | 114045 | 1.500 |
Why?
|
| Eye Injuries | 3 | 2024 | 42 | 1.500 |
Why?
|
| Prostate | 12 | 2022 | 157 | 1.460 |
Why?
|
| Grape Seed Extract | 14 | 2019 | 41 | 1.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 20 | 2018 | 1145 | 1.380 |
Why?
|
| Colonic Neoplasms | 10 | 2018 | 212 | 1.340 |
Why?
|
| Dose-Response Relationship, Drug | 29 | 2021 | 1836 | 1.340 |
Why?
|
| Blister | 7 | 2017 | 43 | 1.300 |
Why?
|
| Epidermis | 6 | 2014 | 148 | 1.290 |
Why?
|
| Caspases | 16 | 2012 | 243 | 1.280 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2022 | 445 | 1.260 |
Why?
|
| Neoplastic Stem Cells | 6 | 2019 | 327 | 1.260 |
Why?
|
| Enzyme Activation | 20 | 2020 | 771 | 1.240 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2020 | 636 | 1.220 |
Why?
|
| Blotting, Western | 21 | 2016 | 1143 | 1.210 |
Why?
|
| Transcription Factor AP-1 | 9 | 2016 | 81 | 1.210 |
Why?
|
| Chemoprevention | 12 | 2019 | 87 | 1.210 |
Why?
|
| Skin Diseases | 4 | 2017 | 121 | 1.210 |
Why?
|
| Phosphorylation | 26 | 2019 | 1558 | 1.200 |
Why?
|
| Immunohistochemistry | 22 | 2019 | 1624 | 1.200 |
Why?
|
| Corneal Neovascularization | 3 | 2017 | 12 | 1.190 |
Why?
|
| Keratinocytes | 5 | 2020 | 215 | 1.180 |
Why?
|
| Matrix Metalloproteinase 9 | 10 | 2021 | 118 | 1.170 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2013 | 196 | 1.170 |
Why?
|
| Tumor Cells, Cultured | 26 | 2021 | 845 | 1.150 |
Why?
|
| Transcription Factors | 9 | 2014 | 1526 | 1.130 |
Why?
|
| Enzyme Inhibitors | 11 | 2013 | 743 | 1.130 |
Why?
|
| Caspase 3 | 12 | 2019 | 234 | 1.120 |
Why?
|
| DNA Repair | 6 | 2015 | 184 | 1.100 |
Why?
|
| Cell Movement | 12 | 2019 | 863 | 1.100 |
Why?
|
| Biomarkers | 6 | 2024 | 3397 | 1.090 |
Why?
|
| STAT3 Transcription Factor | 9 | 2013 | 172 | 1.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 11 | 2012 | 69 | 1.080 |
Why?
|
| Fibroblasts | 4 | 2016 | 834 | 1.060 |
Why?
|
| Metabolomics | 5 | 2019 | 511 | 1.050 |
Why?
|
| Neoplasm Invasiveness | 10 | 2020 | 438 | 1.010 |
Why?
|
| Antidotes | 5 | 2017 | 135 | 1.000 |
Why?
|
| Microtubule-Associated Proteins | 8 | 2017 | 171 | 1.000 |
Why?
|
| Seeds | 13 | 2013 | 74 | 0.970 |
Why?
|
| Down-Regulation | 14 | 2014 | 594 | 0.970 |
Why?
|
| Hedgehog Proteins | 4 | 2022 | 172 | 0.940 |
Why?
|
| Phosgene | 3 | 2024 | 6 | 0.930 |
Why?
|
| Epithelium, Corneal | 4 | 2019 | 35 | 0.920 |
Why?
|
| beta Catenin | 9 | 2018 | 218 | 0.920 |
Why?
|
| Anthocyanins | 6 | 2019 | 28 | 0.920 |
Why?
|
| Azoxymethane | 7 | 2022 | 16 | 0.910 |
Why?
|
| Inflammation | 10 | 2024 | 2464 | 0.910 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 9 | 2017 | 145 | 0.900 |
Why?
|
| Exosomes | 3 | 2020 | 92 | 0.870 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2017 | 577 | 0.850 |
Why?
|
| Endoplasmic Reticulum Stress | 6 | 2017 | 92 | 0.850 |
Why?
|
| Patched-1 Receptor | 2 | 2022 | 15 | 0.850 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2022 | 307 | 0.850 |
Why?
|
| Cell Division | 22 | 2015 | 754 | 0.840 |
Why?
|
| ErbB Receptors | 6 | 2017 | 554 | 0.840 |
Why?
|
| Cyclin D1 | 12 | 2019 | 61 | 0.840 |
Why?
|
| DNA-Binding Proteins | 11 | 2015 | 1311 | 0.820 |
Why?
|
| G1 Phase | 7 | 2009 | 68 | 0.820 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2017 | 959 | 0.820 |
Why?
|
| Cyclin-Dependent Kinases | 10 | 2008 | 111 | 0.820 |
Why?
|
| Indoles | 4 | 2019 | 300 | 0.810 |
Why?
|
| Neoplasm Proteins | 8 | 2014 | 385 | 0.800 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 8 | 2017 | 164 | 0.800 |
Why?
|
| Cyclins | 9 | 2009 | 78 | 0.780 |
Why?
|
| Tumor Microenvironment | 2 | 2016 | 428 | 0.780 |
Why?
|
| Deoxycytidine | 2 | 2020 | 138 | 0.780 |
Why?
|
| Carcinogens | 8 | 2013 | 102 | 0.770 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2019 | 74 | 0.770 |
Why?
|
| Mast Cells | 3 | 2019 | 116 | 0.760 |
Why?
|
| Autophagy | 7 | 2018 | 235 | 0.760 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2008 | 38 | 0.760 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 521 | 0.750 |
Why?
|
| Mice, Inbred C57BL | 19 | 2024 | 4680 | 0.750 |
Why?
|
| Peroxidase | 8 | 2015 | 161 | 0.740 |
Why?
|
| Mice, Transgenic | 13 | 2019 | 1947 | 0.740 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2017 | 1356 | 0.730 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2017 | 388 | 0.730 |
Why?
|
| Cation Transport Proteins | 1 | 2022 | 123 | 0.720 |
Why?
|
| Reactive Oxygen Species | 13 | 2023 | 522 | 0.720 |
Why?
|
| Matrix Metalloproteinases | 2 | 2020 | 89 | 0.710 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2019 | 283 | 0.710 |
Why?
|
| Cell Death | 11 | 2023 | 322 | 0.710 |
Why?
|
| Cell Line | 11 | 2020 | 2629 | 0.700 |
Why?
|
| Flavonolignans | 5 | 2012 | 10 | 0.700 |
Why?
|
| Drug Resistance | 1 | 2020 | 158 | 0.690 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2016 | 250 | 0.680 |
Why?
|
| Corneal Stroma | 2 | 2017 | 15 | 0.670 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.670 |
Why?
|
| Stilbenes | 5 | 2015 | 36 | 0.660 |
Why?
|
| Biological Products | 2 | 2015 | 166 | 0.660 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 1032 | 0.650 |
Why?
|
| MicroRNAs | 3 | 2020 | 600 | 0.630 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 6 | 2010 | 38 | 0.630 |
Why?
|
| Protein Kinases | 3 | 2013 | 304 | 0.620 |
Why?
|
| Inflammation Mediators | 5 | 2024 | 475 | 0.620 |
Why?
|
| Sesquiterpenes | 3 | 2016 | 51 | 0.620 |
Why?
|
| Oximes | 2 | 2024 | 19 | 0.610 |
Why?
|
| Head and Neck Neoplasms | 5 | 2015 | 427 | 0.610 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 209 | 0.590 |
Why?
|
| Dermis | 2 | 2015 | 30 | 0.570 |
Why?
|
| Poly(ADP-ribose) Polymerases | 12 | 2019 | 87 | 0.570 |
Why?
|
| STAT1 Transcription Factor | 4 | 2013 | 63 | 0.570 |
Why?
|
| Interleukin-8 | 4 | 2021 | 229 | 0.570 |
Why?
|
| Proliferating Cell Nuclear Antigen | 10 | 2010 | 49 | 0.570 |
Why?
|
| Integrins | 2 | 2015 | 80 | 0.570 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 295 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2005 | 607 | 0.560 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2008 | 53 | 0.560 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 2 | 2018 | 8 | 0.550 |
Why?
|
| Carcinogenesis | 6 | 2022 | 175 | 0.550 |
Why?
|
| Intestine, Small | 3 | 2014 | 121 | 0.550 |
Why?
|
| Time Factors | 15 | 2017 | 6077 | 0.540 |
Why?
|
| Doxycycline | 2 | 2017 | 54 | 0.540 |
Why?
|
| Necrosis | 2 | 2015 | 209 | 0.540 |
Why?
|
| Flavonoids | 5 | 2017 | 66 | 0.530 |
Why?
|
| NFATC Transcription Factors | 2 | 2016 | 78 | 0.530 |
Why?
|
| Alkylating Agents | 2 | 2013 | 27 | 0.530 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2016 | 14 | 0.520 |
Why?
|
| Lipogenesis | 1 | 2016 | 56 | 0.520 |
Why?
|
| Histones | 9 | 2019 | 529 | 0.520 |
Why?
|
| Mitochondria | 10 | 2017 | 744 | 0.520 |
Why?
|
| In Situ Nick-End Labeling | 11 | 2015 | 119 | 0.520 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 104 | 0.510 |
Why?
|
| Drug Screening Assays, Antitumor | 10 | 2021 | 181 | 0.510 |
Why?
|
| Cytochromes c | 6 | 2016 | 60 | 0.510 |
Why?
|
| Disease Progression | 11 | 2017 | 2371 | 0.500 |
Why?
|
| Hydroxamic Acids | 2 | 2013 | 80 | 0.500 |
Why?
|
| Oxidation-Reduction | 9 | 2020 | 917 | 0.500 |
Why?
|
| Epidermal Growth Factor | 5 | 2013 | 160 | 0.500 |
Why?
|
| Gallic Acid | 4 | 2009 | 13 | 0.500 |
Why?
|
| Flavones | 3 | 2017 | 10 | 0.500 |
Why?
|
| Doxorubicin | 4 | 2017 | 286 | 0.500 |
Why?
|
| Microscopy, Confocal | 5 | 2015 | 304 | 0.490 |
Why?
|
| Glutathione | 3 | 2011 | 293 | 0.490 |
Why?
|
| Receptors, Androgen | 3 | 2013 | 131 | 0.490 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 167 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3039 | 0.490 |
Why?
|
| Spheroids, Cellular | 2 | 2019 | 56 | 0.490 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2006 | 66 | 0.480 |
Why?
|
| Hematopoietic System | 1 | 2014 | 8 | 0.480 |
Why?
|
| Interleukin-4 | 3 | 2014 | 204 | 0.480 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 54 | 0.470 |
Why?
|
| Retinoblastoma Protein | 3 | 2004 | 52 | 0.470 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2013 | 197 | 0.460 |
Why?
|
| Epigenesis, Genetic | 3 | 2013 | 518 | 0.460 |
Why?
|
| Nuclear Proteins | 3 | 2015 | 591 | 0.460 |
Why?
|
| Fibronectins | 1 | 2014 | 108 | 0.450 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2017 | 170 | 0.450 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 2014 | 20 | 0.450 |
Why?
|
| Up-Regulation | 6 | 2013 | 802 | 0.450 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2014 | 39 | 0.450 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2014 | 31 | 0.440 |
Why?
|
| Epithelial Cells | 5 | 2019 | 946 | 0.440 |
Why?
|
| HT29 Cells | 7 | 2018 | 35 | 0.440 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 6 | 2017 | 62 | 0.430 |
Why?
|
| Protein Biosynthesis | 2 | 2013 | 386 | 0.430 |
Why?
|
| Plant Lectins | 3 | 2018 | 8 | 0.430 |
Why?
|
| Carboplatin | 2 | 2004 | 135 | 0.430 |
Why?
|
| Momordica | 1 | 2013 | 2 | 0.430 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 345 | 0.430 |
Why?
|
| Cells, Cultured | 13 | 2019 | 3861 | 0.430 |
Why?
|
| Cell Growth Processes | 7 | 2016 | 51 | 0.420 |
Why?
|
| Proteomics | 4 | 2024 | 815 | 0.420 |
Why?
|
| Radiation-Protective Agents | 3 | 2013 | 26 | 0.420 |
Why?
|
| Structure-Activity Relationship | 8 | 2021 | 499 | 0.420 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2010 | 18 | 0.420 |
Why?
|
| Spleen | 1 | 2014 | 485 | 0.420 |
Why?
|
| RANK Ligand | 1 | 2012 | 26 | 0.410 |
Why?
|
| Androgens | 3 | 2018 | 167 | 0.410 |
Why?
|
| Osteoclasts | 1 | 2012 | 34 | 0.410 |
Why?
|
| Oryza | 3 | 2022 | 20 | 0.410 |
Why?
|
| Comfrey | 1 | 2012 | 2 | 0.410 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 410 | 0.410 |
Why?
|
| Glyceric Acids | 1 | 2012 | 6 | 0.410 |
Why?
|
| Interleukin-12 | 1 | 2013 | 110 | 0.400 |
Why?
|
| Corneal Diseases | 1 | 2012 | 32 | 0.400 |
Why?
|
| Cisplatin | 2 | 2004 | 262 | 0.400 |
Why?
|
| cdc25 Phosphatases | 3 | 2008 | 12 | 0.400 |
Why?
|
| Acetylcysteine | 4 | 2023 | 141 | 0.400 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 1846 | 0.390 |
Why?
|
| Immunoblotting | 10 | 2017 | 282 | 0.390 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2012 | 18 | 0.390 |
Why?
|
| Pyrimidine Dimers | 3 | 2011 | 7 | 0.390 |
Why?
|
| Cell Hypoxia | 4 | 2016 | 221 | 0.390 |
Why?
|
| Photosensitizing Agents | 1 | 2012 | 24 | 0.390 |
Why?
|
| Dietary Supplements | 5 | 2014 | 459 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 787 | 0.370 |
Why?
|
| Models, Biological | 7 | 2016 | 1611 | 0.370 |
Why?
|
| CDC2 Protein Kinase | 3 | 2006 | 25 | 0.370 |
Why?
|
| Administration, Cutaneous | 3 | 2017 | 117 | 0.370 |
Why?
|
| E2F Transcription Factors | 3 | 2006 | 55 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 1128 | 0.370 |
Why?
|
| Molecular Structure | 9 | 2021 | 434 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1471 | 0.360 |
Why?
|
| Inhibitor of Apoptosis Proteins | 6 | 2011 | 42 | 0.350 |
Why?
|
| Interleukin-6 | 1 | 2014 | 673 | 0.350 |
Why?
|
| Cytokines | 5 | 2013 | 1824 | 0.350 |
Why?
|
| Female | 29 | 2023 | 59324 | 0.350 |
Why?
|
| Transplantation, Heterologous | 7 | 2009 | 180 | 0.340 |
Why?
|
| Proanthocyanidins | 3 | 2019 | 8 | 0.340 |
Why?
|
| Biflavonoids | 3 | 2019 | 8 | 0.340 |
Why?
|
| Endothelial Cells | 5 | 2015 | 677 | 0.340 |
Why?
|
| Corneal Keratocytes | 2 | 2021 | 7 | 0.340 |
Why?
|
| Peptides | 1 | 2015 | 847 | 0.340 |
Why?
|
| Edema | 3 | 2017 | 119 | 0.340 |
Why?
|
| Catechin | 3 | 2019 | 23 | 0.340 |
Why?
|
| RNA, Small Interfering | 5 | 2015 | 534 | 0.340 |
Why?
|
| Dermatitis, Irritant | 1 | 2009 | 11 | 0.330 |
Why?
|
| Cosmetics | 1 | 2009 | 7 | 0.330 |
Why?
|
| Macrophages | 3 | 2019 | 1259 | 0.330 |
Why?
|
| Drug Synergism | 5 | 2013 | 315 | 0.320 |
Why?
|
| Kava | 1 | 2008 | 2 | 0.320 |
Why?
|
| Interferon-gamma | 2 | 2011 | 719 | 0.320 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2008 | 26 | 0.310 |
Why?
|
| Energy Metabolism | 2 | 2014 | 727 | 0.310 |
Why?
|
| Immunoenzyme Techniques | 5 | 2013 | 192 | 0.310 |
Why?
|
| Metformin | 1 | 2012 | 274 | 0.310 |
Why?
|
| Skinfold Thickness | 3 | 2013 | 49 | 0.310 |
Why?
|
| Caspase 9 | 2 | 2013 | 48 | 0.310 |
Why?
|
| Erythema | 3 | 2024 | 25 | 0.300 |
Why?
|
| Cell Differentiation | 7 | 2018 | 1696 | 0.300 |
Why?
|
| Blood Vessels | 2 | 2021 | 179 | 0.300 |
Why?
|
| Butylhydroxybutylnitrosamine | 1 | 2007 | 6 | 0.300 |
Why?
|
| Mice, Knockout | 4 | 2016 | 2562 | 0.300 |
Why?
|
| Kidney | 1 | 2014 | 1182 | 0.300 |
Why?
|
| Transfection | 5 | 2014 | 863 | 0.300 |
Why?
|
| Autocrine Communication | 1 | 2008 | 42 | 0.300 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 53 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 328 | 0.290 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 926 | 0.290 |
Why?
|
| Cytotoxins | 1 | 2007 | 17 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 924 | 0.290 |
Why?
|
| Cell Nucleus | 4 | 2016 | 552 | 0.290 |
Why?
|
| Food | 2 | 2015 | 160 | 0.280 |
Why?
|
| Tannins | 1 | 2007 | 4 | 0.280 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 155 | 0.280 |
Why?
|
| Models, Animal | 3 | 2020 | 340 | 0.280 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2322 | 0.280 |
Why?
|
| Administration, Oral | 6 | 2011 | 725 | 0.280 |
Why?
|
| Organ Culture Techniques | 2 | 2017 | 140 | 0.270 |
Why?
|
| RNA, Messenger | 5 | 2010 | 2550 | 0.270 |
Why?
|
| Caspase 2 | 1 | 2006 | 14 | 0.270 |
Why?
|
| Growth Inhibitors | 4 | 2013 | 43 | 0.270 |
Why?
|
| Body Weight | 4 | 2014 | 868 | 0.260 |
Why?
|
| DNA | 3 | 2010 | 1350 | 0.260 |
Why?
|
| Tyrosine | 2 | 2013 | 210 | 0.260 |
Why?
|
| Biomedical Research | 1 | 2011 | 582 | 0.260 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 504 | 0.250 |
Why?
|
| Wnt Proteins | 3 | 2018 | 134 | 0.250 |
Why?
|
| S Phase | 1 | 2005 | 69 | 0.250 |
Why?
|
| Plants | 1 | 2007 | 193 | 0.240 |
Why?
|
| Benzopyrans | 1 | 2005 | 25 | 0.240 |
Why?
|
| Neoplasm Transplantation | 5 | 2014 | 227 | 0.240 |
Why?
|
| Cytoprotection | 3 | 2015 | 51 | 0.240 |
Why?
|
| Rad51 Recombinase | 2 | 2015 | 14 | 0.240 |
Why?
|
| Glycosides | 1 | 2005 | 33 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2012 | 33 | 0.230 |
Why?
|
| Butyrates | 1 | 2005 | 53 | 0.230 |
Why?
|
| Cysteine | 2 | 2020 | 171 | 0.230 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2018 | 286 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 210 | 0.230 |
Why?
|
| Deoxyguanosine | 2 | 2015 | 26 | 0.220 |
Why?
|
| Lipid Metabolism | 4 | 2020 | 441 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 296 | 0.220 |
Why?
|
| HCT116 Cells | 3 | 2014 | 70 | 0.220 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 532 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 2 | 3 | 2012 | 32 | 0.220 |
Why?
|
| Unfolded Protein Response | 1 | 2023 | 44 | 0.220 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 5 | 2015 | 88 | 0.210 |
Why?
|
| Pentacyclic Triterpenes | 2 | 2014 | 13 | 0.210 |
Why?
|
| Actin Cytoskeleton | 1 | 2024 | 93 | 0.210 |
Why?
|
| Flow Cytometry | 5 | 2010 | 1075 | 0.210 |
Why?
|
| Nucleotides | 1 | 2023 | 112 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 86 | 0.210 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 1003 | 0.210 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 158 | 0.210 |
Why?
|
| Bifidobacterium longum | 1 | 2022 | 5 | 0.200 |
Why?
|
| Mitochondrial Proteins | 1 | 2004 | 213 | 0.200 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2022 | 11 | 0.200 |
Why?
|
| Cell Cycle Checkpoints | 4 | 2016 | 84 | 0.200 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2013 | 181 | 0.200 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2009 | 57 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 3 | 2013 | 1144 | 0.200 |
Why?
|
| Organ Size | 2 | 2014 | 434 | 0.200 |
Why?
|
| Ligands | 1 | 2024 | 556 | 0.190 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2012 | 26 | 0.190 |
Why?
|
| Carrier Proteins | 2 | 2022 | 694 | 0.190 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 830 | 0.190 |
Why?
|
| Actins | 1 | 2024 | 376 | 0.190 |
Why?
|
| Serine Endopeptidases | 1 | 2022 | 101 | 0.190 |
Why?
|
| Protein Transport | 3 | 2011 | 391 | 0.190 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2021 | 12 | 0.190 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2017 | 44 | 0.190 |
Why?
|
| Curcumin | 1 | 2021 | 28 | 0.180 |
Why?
|
| Biological Assay | 2 | 2016 | 112 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 270 | 0.180 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 170 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2015 | 113 | 0.180 |
Why?
|
| Hypoxia | 2 | 2019 | 956 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 386 | 0.180 |
Why?
|
| Chromones | 2 | 2014 | 35 | 0.180 |
Why?
|
| Radiation Tolerance | 2 | 2015 | 92 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 179 | 0.170 |
Why?
|
| Aldehydes | 2 | 2012 | 138 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2020 | 5 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 80 | 0.170 |
Why?
|
| Caspase 8 | 2 | 2010 | 43 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 121 | 0.170 |
Why?
|
| Antiviral Agents | 2 | 2018 | 642 | 0.170 |
Why?
|
| Intestinal Polyps | 2 | 2010 | 15 | 0.170 |
Why?
|
| Lipids | 1 | 2023 | 564 | 0.170 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2019 | 20 | 0.170 |
Why?
|
| Gene Expression | 3 | 2015 | 1417 | 0.170 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 26 | 0.170 |
Why?
|
| Species Specificity | 2 | 2013 | 541 | 0.170 |
Why?
|
| Mitogens | 2 | 2013 | 58 | 0.170 |
Why?
|
| Janus Kinase 1 | 2 | 2011 | 23 | 0.170 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 61 | 0.170 |
Why?
|
| Morpholines | 2 | 2014 | 102 | 0.170 |
Why?
|
| Protein Carbonylation | 1 | 2019 | 51 | 0.170 |
Why?
|
| Respiratory System | 1 | 2020 | 137 | 0.170 |
Why?
|
| Mice, Inbred Strains | 4 | 2017 | 398 | 0.160 |
Why?
|
| Pesticides | 1 | 2019 | 49 | 0.160 |
Why?
|
| Cyclin E | 2 | 2012 | 21 | 0.160 |
Why?
|
| Triterpenes | 2 | 2010 | 17 | 0.160 |
Why?
|
| DNA, Neoplasm | 2 | 2010 | 155 | 0.160 |
Why?
|
| Lanosterol | 2 | 2009 | 2 | 0.160 |
Why?
|
| Zinc | 1 | 2022 | 257 | 0.160 |
Why?
|
| Lipid Peroxidation | 2 | 2019 | 139 | 0.160 |
Why?
|
| Oncogene Protein v-akt | 2 | 2009 | 26 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 159 | 0.160 |
Why?
|
| Cytosol | 2 | 2013 | 201 | 0.160 |
Why?
|
| Kinetics | 3 | 2014 | 1547 | 0.160 |
Why?
|
| Urethane | 2 | 2010 | 41 | 0.160 |
Why?
|
| Body Fluids | 1 | 2019 | 58 | 0.160 |
Why?
|
| Tumor Burden | 3 | 2020 | 258 | 0.150 |
Why?
|
| Dermatitis | 2 | 2010 | 17 | 0.150 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 3 | 2016 | 238 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2012 | 127 | 0.150 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2018 | 10 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2020 | 221 | 0.150 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2018 | 11 | 0.150 |
Why?
|
| CD24 Antigen | 1 | 2018 | 20 | 0.150 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 103 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2016 | 9049 | 0.150 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 307 | 0.150 |
Why?
|
| Glycoconjugates | 1 | 2018 | 7 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2008 | 7 | 0.150 |
Why?
|
| Corneal Pachymetry | 1 | 2017 | 14 | 0.150 |
Why?
|
| Hyaluronan Receptors | 1 | 2018 | 90 | 0.150 |
Why?
|
| Checkpoint Kinase 2 | 3 | 2006 | 21 | 0.150 |
Why?
|
| Keratitis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Arsenic Poisoning | 1 | 2017 | 7 | 0.150 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 337 | 0.150 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Dimerization | 3 | 2011 | 176 | 0.150 |
Why?
|
| Tumor Protein p73 | 1 | 2017 | 14 | 0.150 |
Why?
|
| Proteome | 2 | 2019 | 337 | 0.140 |
Why?
|
| Diet | 4 | 2022 | 1080 | 0.140 |
Why?
|
| Glucose | 2 | 2015 | 899 | 0.140 |
Why?
|
| Triglycerides | 2 | 2020 | 467 | 0.140 |
Why?
|
| Consensus | 1 | 2020 | 532 | 0.140 |
Why?
|
| Laminin | 3 | 2013 | 69 | 0.140 |
Why?
|
| Protein Binding | 3 | 2017 | 1888 | 0.140 |
Why?
|
| Receptors, Notch | 1 | 2018 | 83 | 0.140 |
Why?
|
| Organophosphates | 1 | 2018 | 90 | 0.140 |
Why?
|
| Microcirculation | 2 | 2008 | 133 | 0.140 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2017 | 6 | 0.140 |
Why?
|
| Heterografts | 2 | 2015 | 117 | 0.140 |
Why?
|
| Adipose Tissue | 1 | 2020 | 545 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 70 | 0.140 |
Why?
|
| Proteoglycans | 3 | 2013 | 107 | 0.140 |
Why?
|
| Autophagy-Related Proteins | 1 | 2017 | 39 | 0.140 |
Why?
|
| HIV | 1 | 2018 | 208 | 0.130 |
Why?
|
| Pleckstrin Homology Domains | 1 | 2016 | 1 | 0.130 |
Why?
|
| Drug Combinations | 3 | 2013 | 286 | 0.130 |
Why?
|
| Ribosome Inactivating Proteins, Type 2 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 347 | 0.130 |
Why?
|
| Administration, Topical | 2 | 2008 | 137 | 0.130 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2014 | 33 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 907 | 0.130 |
Why?
|
| Talaromyces | 1 | 2016 | 3 | 0.130 |
Why?
|
| NADPH Oxidase 1 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Annonaceae | 1 | 2016 | 4 | 0.130 |
Why?
|
| Corneal Opacity | 1 | 2016 | 6 | 0.130 |
Why?
|
| Bromodeoxyuridine | 2 | 2007 | 72 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2020 | 655 | 0.130 |
Why?
|
| Terpenes | 1 | 2016 | 21 | 0.130 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 42 | 0.130 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2015 | 5 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 502 | 0.130 |
Why?
|
| Metabolome | 1 | 2019 | 274 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 55 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 65 | 0.130 |
Why?
|
| Pyrones | 1 | 2015 | 9 | 0.130 |
Why?
|
| NADPH Oxidases | 1 | 2016 | 105 | 0.130 |
Why?
|
| Naphthols | 1 | 2015 | 7 | 0.130 |
Why?
|
| Mitosis | 2 | 2007 | 164 | 0.130 |
Why?
|
| Rupture | 1 | 2016 | 96 | 0.130 |
Why?
|
| Solanum tuberosum | 1 | 2015 | 7 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 38 | 0.130 |
Why?
|
| Naphthalenes | 1 | 2015 | 38 | 0.120 |
Why?
|
| Skin Absorption | 1 | 2015 | 11 | 0.120 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 436 | 0.120 |
Why?
|
| Eye | 1 | 2016 | 97 | 0.120 |
Why?
|
| Microsomes, Liver | 2 | 2012 | 54 | 0.120 |
Why?
|
| Collagen | 3 | 2013 | 414 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 445 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1162 | 0.120 |
Why?
|
| Electron Transport Complex III | 1 | 2014 | 11 | 0.120 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.120 |
Why?
|
| Colon | 2 | 2022 | 232 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 115 | 0.120 |
Why?
|
| Glioma | 2 | 2011 | 285 | 0.120 |
Why?
|
| Quinazolines | 1 | 2016 | 240 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2015 | 133 | 0.120 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 103 | 0.120 |
Why?
|
| Extracellular Vesicles | 1 | 2015 | 83 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2014 | 40 | 0.110 |
Why?
|
| Membrane Potentials | 2 | 2005 | 247 | 0.110 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 41 | 0.110 |
Why?
|
| Thiazoles | 1 | 2014 | 110 | 0.110 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 19 | 0.110 |
Why?
|
| Glucuronides | 2 | 2011 | 12 | 0.110 |
Why?
|
| Allografts | 1 | 2014 | 121 | 0.110 |
Why?
|
| Boron Compounds | 1 | 2014 | 17 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2014 | 399 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2014 | 292 | 0.110 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2013 | 8 | 0.110 |
Why?
|
| Caspase Inhibitors | 2 | 2004 | 77 | 0.110 |
Why?
|
| Adherens Junctions | 1 | 2013 | 26 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 429 | 0.110 |
Why?
|
| Tongue Neoplasms | 1 | 2013 | 20 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2016 | 440 | 0.110 |
Why?
|
| Metalloporphyrins | 1 | 2014 | 103 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1257 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2011 | 211 | 0.110 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 23 | 0.110 |
Why?
|
| Somatomedins | 1 | 2013 | 28 | 0.110 |
Why?
|
| Vacuoles | 1 | 2013 | 33 | 0.110 |
Why?
|
| Adipocytes | 1 | 2014 | 188 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2012 | 474 | 0.110 |
Why?
|
| Cell Shape | 1 | 2013 | 54 | 0.100 |
Why?
|
| Dietary Fiber | 1 | 2013 | 40 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 301 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 396 | 0.100 |
Why?
|
| G2 Phase | 2 | 2012 | 31 | 0.100 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2012 | 36 | 0.100 |
Why?
|
| Macrolides | 1 | 2013 | 57 | 0.100 |
Why?
|
| A549 Cells | 3 | 2017 | 51 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 41 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2012 | 23 | 0.100 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 72 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2019 | 145 | 0.100 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2012 | 14 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 241 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 966 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2013 | 171 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 587 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 57 | 0.100 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2011 | 5 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 250 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2007 | 161 | 0.100 |
Why?
|
| Transcription Factor CHOP | 1 | 2012 | 28 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 37 | 0.100 |
Why?
|
| Acetylation | 1 | 2012 | 209 | 0.100 |
Why?
|
| Genes, erbB-1 | 1 | 2011 | 17 | 0.100 |
Why?
|
| Azacitidine | 1 | 2013 | 129 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2014 | 379 | 0.100 |
Why?
|
| Chromans | 1 | 2011 | 21 | 0.100 |
Why?
|
| Rats, Inbred F344 | 2 | 2010 | 241 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 61 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 1206 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.090 |
Why?
|
| Random Allocation | 2 | 2010 | 328 | 0.090 |
Why?
|
| Flavonols | 3 | 2017 | 11 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 157 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 34 | 0.090 |
Why?
|
| Adenine | 1 | 2013 | 218 | 0.090 |
Why?
|
| Pyridines | 1 | 2014 | 419 | 0.090 |
Why?
|
| Phenotype | 1 | 2019 | 2784 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 68 | 0.090 |
Why?
|
| Buthionine Sulfoximine | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2012 | 228 | 0.090 |
Why?
|
| Oxygen | 1 | 2015 | 851 | 0.090 |
Why?
|
| Nestin | 1 | 2010 | 16 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 271 | 0.090 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 65 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 73 | 0.090 |
Why?
|
| Angiogenic Proteins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Alleles | 1 | 2013 | 789 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2011 | 88 | 0.090 |
Why?
|
| Genes, APC | 1 | 2010 | 13 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 174 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 359 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 80 | 0.090 |
Why?
|
| Lung | 2 | 2014 | 3521 | 0.090 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 82 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2010 | 38 | 0.090 |
Why?
|
| Lactoferrin | 1 | 2010 | 27 | 0.090 |
Why?
|
| RNA Interference | 1 | 2011 | 431 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2010 | 31 | 0.080 |
Why?
|
| Deoxyadenosines | 1 | 2009 | 7 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2010 | 47 | 0.080 |
Why?
|
| Arachidonic Acid | 1 | 2010 | 112 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 234 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2014 | 52 | 0.080 |
Why?
|
| Phospholipases A | 1 | 2010 | 95 | 0.080 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 30 | 0.080 |
Why?
|
| Hepatitis | 1 | 2010 | 45 | 0.080 |
Why?
|
| Skin Care | 1 | 2009 | 18 | 0.080 |
Why?
|
| Skin Aging | 1 | 2009 | 19 | 0.080 |
Why?
|
| Intestinal Neoplasms | 1 | 2009 | 24 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 949 | 0.080 |
Why?
|
| Esthetics | 1 | 2009 | 37 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 465 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2010 | 183 | 0.080 |
Why?
|
| Inositol | 1 | 2009 | 23 | 0.080 |
Why?
|
| Cell Polarity | 1 | 2010 | 131 | 0.080 |
Why?
|
| Citrates | 1 | 2009 | 42 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 165 | 0.080 |
Why?
|
| I-kappa B Proteins | 2 | 2014 | 80 | 0.080 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2016 | 55 | 0.080 |
Why?
|
| Apiaceae | 1 | 2009 | 1 | 0.080 |
Why?
|
| Furocoumarins | 1 | 2009 | 8 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2010 | 356 | 0.080 |
Why?
|
| Rats | 4 | 2013 | 4913 | 0.080 |
Why?
|
| Dermatologic Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
| Wound Healing | 1 | 2011 | 254 | 0.080 |
Why?
|
| Polyporales | 1 | 2008 | 1 | 0.080 |
Why?
|
| Plant Roots | 1 | 2009 | 34 | 0.080 |
Why?
|
| Oxidative Phosphorylation | 1 | 2009 | 154 | 0.080 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2008 | 12 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2017 | 2958 | 0.080 |
Why?
|
| Fruit | 1 | 2009 | 119 | 0.080 |
Why?
|
| Vimentin | 1 | 2008 | 58 | 0.080 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 94 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 177 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 347 | 0.080 |
Why?
|
| Isomerism | 1 | 2008 | 43 | 0.080 |
Why?
|
| Antimitotic Agents | 1 | 2008 | 8 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2010 | 125 | 0.080 |
Why?
|
| Beverages | 1 | 2008 | 60 | 0.080 |
Why?
|
| Choline | 1 | 2009 | 106 | 0.080 |
Why?
|
| Microvessels | 1 | 2009 | 66 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 15 | 0.070 |
Why?
|
| ets-Domain Protein Elk-1 | 2 | 2005 | 13 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2008 | 18 | 0.070 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 108 | 0.070 |
Why?
|
| Mutation | 3 | 2020 | 3338 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2007 | 12 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 2355 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 142 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 151 | 0.070 |
Why?
|
| Monocytes | 1 | 2010 | 503 | 0.070 |
Why?
|
| Abrus | 2 | 2017 | 2 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 31 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 133 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2007 | 91 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 527 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2010 | 348 | 0.070 |
Why?
|
| I-kappa B Kinase | 2 | 2003 | 50 | 0.070 |
Why?
|
| Toluene | 1 | 2006 | 11 | 0.070 |
Why?
|
| Ornithine Decarboxylase | 1 | 2006 | 9 | 0.070 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2006 | 22 | 0.070 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2006 | 13 | 0.070 |
Why?
|
| Benzothiazoles | 1 | 2006 | 31 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2006 | 58 | 0.070 |
Why?
|
| Anoikis | 1 | 2006 | 31 | 0.070 |
Why?
|
| Cyclin D3 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 82 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 1131 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1218 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 990 | 0.060 |
Why?
|
| Ataxia Telangiectasia | 1 | 2005 | 17 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2005 | 21 | 0.060 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 28 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2003 | 66 | 0.060 |
Why?
|
| Chrysanthemum | 1 | 2005 | 2 | 0.060 |
Why?
|
| Rhamnose | 1 | 2005 | 3 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2005 | 60 | 0.060 |
Why?
|
| HeLa Cells | 2 | 2017 | 563 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2004 | 53 | 0.060 |
Why?
|
| Plant Oils | 1 | 2004 | 26 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2008 | 367 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 77 | 0.060 |
Why?
|
| Light | 1 | 2007 | 336 | 0.060 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 18 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 73 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 248 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 324 | 0.060 |
Why?
|
| Papilloma | 1 | 2003 | 42 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2003 | 15 | 0.060 |
Why?
|
| Eyelids | 1 | 2024 | 27 | 0.060 |
Why?
|
| Cell Communication | 1 | 2005 | 277 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2004 | 68 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2015 | 45 | 0.060 |
Why?
|
| Cytochrome c Group | 1 | 2003 | 35 | 0.060 |
Why?
|
| Animal Feed | 1 | 2004 | 49 | 0.060 |
Why?
|
| Sphingolipids | 1 | 2024 | 57 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2016 | 300 | 0.050 |
Why?
|
| E2F4 Transcription Factor | 1 | 2003 | 6 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2023 | 13 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 102 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 393 | 0.050 |
Why?
|
| Comet Assay | 2 | 2014 | 18 | 0.050 |
Why?
|
| Transgenes | 1 | 2003 | 170 | 0.050 |
Why?
|
| Lipoxygenase | 1 | 2002 | 12 | 0.050 |
Why?
|
| E2F3 Transcription Factor | 1 | 2002 | 8 | 0.050 |
Why?
|
| E2F2 Transcription Factor | 1 | 2002 | 15 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 88 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2002 | 53 | 0.050 |
Why?
|
| Dextran Sulfate | 1 | 2022 | 70 | 0.050 |
Why?
|
| Mice, Inbred SENCAR | 1 | 2002 | 1 | 0.050 |
Why?
|
| Liver | 1 | 2010 | 1633 | 0.050 |
Why?
|
| E2F1 Transcription Factor | 1 | 2002 | 57 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2017 | 1368 | 0.050 |
Why?
|
| Mammary Glands, Animal | 1 | 2002 | 117 | 0.050 |
Why?
|
| Methylation | 2 | 2012 | 208 | 0.050 |
Why?
|
| Serine | 1 | 2002 | 125 | 0.050 |
Why?
|
| Corticosterone | 1 | 2002 | 211 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 371 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2002 | 266 | 0.050 |
Why?
|
| Ranolazine | 1 | 2020 | 22 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 188 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 367 | 0.040 |
Why?
|
| Social Control, Formal | 1 | 2020 | 11 | 0.040 |
Why?
|
| Energy Intake | 1 | 2002 | 427 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 51 | 0.040 |
Why?
|
| India | 1 | 2020 | 134 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 51 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1518 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 784 | 0.040 |
Why?
|
| Jagged-1 Protein | 1 | 2019 | 22 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 68 | 0.040 |
Why?
|
| Filamins | 1 | 2019 | 19 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2019 | 59 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 145 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 50 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 162 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2002 | 965 | 0.040 |
Why?
|
| Circulating MicroRNA | 1 | 2018 | 24 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2020 | 435 | 0.040 |
Why?
|
| Proteolysis | 1 | 2018 | 142 | 0.040 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2018 | 64 | 0.040 |
Why?
|
| Mouth | 1 | 2017 | 69 | 0.040 |
Why?
|
| Poisoning | 1 | 2017 | 110 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 2017 | 66 | 0.030 |
Why?
|
| Nuclear Localization Signals | 1 | 2016 | 14 | 0.030 |
Why?
|
| Alkaloids | 1 | 2016 | 22 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 215 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 46 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2016 | 24 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2016 | 31 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 105 | 0.030 |
Why?
|
| Stomach | 1 | 2016 | 102 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 373 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 285 | 0.030 |
Why?
|
| Diketopiperazines | 1 | 2015 | 8 | 0.030 |
Why?
|
| Penicillium | 1 | 2015 | 6 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 686 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 135 | 0.030 |
Why?
|
| Sulindac | 1 | 2015 | 17 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 660 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 71 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 45 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1024 | 0.030 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 43 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 54 | 0.030 |
Why?
|
| Plant Leaves | 1 | 2016 | 110 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2014 | 32 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 402 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 99 | 0.030 |
Why?
|
| Annexin A2 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Tetraspanins | 1 | 2013 | 15 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 260 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2014 | 26 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 2014 | 60 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2013 | 3 | 0.030 |
Why?
|
| Metalloproteases | 1 | 2013 | 37 | 0.030 |
Why?
|
| Tongue | 1 | 2013 | 66 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 213 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 122 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 2013 | 45 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 479 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 198 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 156 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 112 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 144 | 0.030 |
Why?
|
| Capillaries | 1 | 2013 | 90 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2012 | 17 | 0.030 |
Why?
|
| Calcium | 1 | 2019 | 1089 | 0.030 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2013 | 13 | 0.030 |
Why?
|
| Vitamin E | 1 | 2013 | 110 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2012 | 61 | 0.030 |
Why?
|
| Transcriptome | 1 | 2018 | 723 | 0.030 |
Why?
|
| Superoxides | 1 | 2013 | 190 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 255 | 0.030 |
Why?
|
| Phenols | 1 | 2013 | 82 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2013 | 368 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1381 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 393 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 873 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 133 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2011 | 56 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1277 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 742 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2764 | 0.020 |
Why?
|
| Ethanol | 1 | 2015 | 534 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2010 | 74 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2010 | 97 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 508 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 590 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 271 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2010 | 123 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 286 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 151 | 0.020 |
Why?
|
| Picrates | 1 | 2008 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 116 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2008 | 43 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 426 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 50 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2010 | 294 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 1011 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 368 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 580 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1117 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 918 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 2114 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2006 | 73 | 0.020 |
Why?
|
| Excipients | 1 | 2006 | 49 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2090 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 103 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 98 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2006 | 27 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2006 | 28 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2006 | 132 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2005 | 23 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2005 | 44 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 182 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2005 | 150 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 465 | 0.010 |
Why?
|
| Densitometry | 1 | 2003 | 29 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 222 | 0.010 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2003 | 10 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 42 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2003 | 47 | 0.010 |
Why?
|
| Anthracenes | 1 | 2003 | 27 | 0.010 |
Why?
|
| Mifepristone | 1 | 2002 | 60 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 137 | 0.010 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 64 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2002 | 163 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 4392 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 906 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 18969 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 26605 | 0.010 |
Why?
|